📣 VC round data is live. Check it out!

EBR Systems Valuation Multiples

Discover revenue and EBITDA valuation multiples for EBR Systems and similar public comparables like Anika Therapeutics, Quantum-Si, Inogen, Lucid Diagnostics and more.

EBR Systems Overview

About EBR Systems

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart. It conducts its operations in the United States.


Founded

2021

HQ

United States

Employees

89

Financials (LTM)

Revenue: $7M
EBITDA: ($48M)

EV

$202M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

EBR Systems Financials

EBR Systems reported last 12-month revenue of $7M and negative EBITDA of ($48M).

In the same LTM period, EBR Systems generated $511K in gross profit, ($48M) in EBITDA losses, and had net loss of ($51M).

Revenue (LTM)


EBR Systems P&L

In the most recent fiscal year, EBR Systems reported revenue of $2M and EBITDA of ($43M).

EBR Systems is unprofitable as of last fiscal year, with gross margin of 30%, EBITDA margin of (2641%), and net margin of (3015%).

See analyst estimates for EBR Systems
LTMLast FY202320242025202620272028
Revenue$7M$2M$2M
Gross Profit$511K$490K$490K
Gross Margin7%30%30%
EBITDA($48M)($43M)($31M)($34M)($43M)
EBITDA Margin(707%)(2641%)(2641%)
EBIT Margin(728%)(2849%)(2850%)
Net Profit($51M)($49M)($35M)($41M)($49M)
Net Margin(748%)(3015%)(3015%)
Net Debt$35M

Financial data powered by Morningstar, Inc.

EBR Systems Stock Performance

EBR Systems has current market cap of $196M, and enterprise value of $202M.

Market Cap Evolution


EBR Systems' stock price is $0.44.

EBR Systems share price decreased by 3.1% in the last 30 days, and by 44.8% in the last year.

EBR Systems has an EPS (earnings per share) of $-0.11.

See more trading valuation data for EBR Systems
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$202M$196M0.0%-3.1%-17.4%-44.8%$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

EBR Systems Valuation Multiples

EBR Systems trades at 29.5x EV/Revenue multiple, and (4.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for EBR Systems

EV / Revenue (LTM)


EBR Systems Financial Valuation Multiples

As of May 12, 2026, EBR Systems has market cap of $196M and EV of $202M.

EBR Systems has a P/E ratio of (3.8x).

LTMLast FY202320242025202620272028
EV/Revenue29.5x124.6x124.6x
EV/EBITDA(4.2x)(4.7x)(6.6x)(5.9x)(4.7x)
EV/EBIT(4.1x)(4.4x)(6.9x)(5.3x)(4.4x)
EV/Gross Profitn/mn/mn/m
P/E(3.8x)(4.0x)(5.6x)(4.8x)(4.0x)
EV/FCF(3.6x)(3.5x)(6.1x)(4.9x)(3.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified EBR Systems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

EBR Systems Margins & Growth Rates

EBR Systems grew revenue by 899% and EBITDA by 27% in the last fiscal year.

In the most recent fiscal year, EBR Systems reported gross margin of 30%, EBITDA margin of (2641%), and net margin of (3015%).

See estimated margins and future growth rates for EBR Systems

EBR Systems Margins

Last FY20252026202720282029
Gross Margin30%30%3%
EBITDA Margin(2641%)(2641%)(337%)
EBIT Margin(2849%)(2850%)(349%)
Net Margin(3015%)(3015%)(342%)
FCF Margin(3517%)(3517%)(331%)

EBR Systems Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth899%899%
Gross Profit Growth2%2%
EBITDA Growth27%12%25%27%
EBIT Growth22%30%20%22%
Net Profit Growth13%16%20%13%
FCF Growth(6%)26%37%(6%)

Data powered by FactSet, Inc. and Morningstar, Inc.

EBR Systems Operational KPIs

EBR Systems' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

EBR Systems' Rule of 40 is 562% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EBR Systems' Rule of X is 1910% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for EBR Systems
LTMLast FY2025202620272028
Rule of 40(430%)562%
Bessemer Rule of X(13%)1910%
Revenue per Employee$0.0M
Opex per Employee$0.5M
S&M Expenses to Revenue50%707%707%
G&A Expenses to Revenue338%1398%692%
R&D Expenses to Revenue361%1481%1481%
Opex to Revenue2880%2880%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EBR Systems Competitors

EBR Systems competitors include Anika Therapeutics, Quantum-Si, Inogen, Lucid Diagnostics, Pro-Dex, Utah Medical, Surgical Science, Ilex Medical, Medinice and Zepp Health.

Most EBR Systems public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Anika Therapeutics1.6x1.6x33.9x25.8x
Quantum-Si30.2x38.0x(0.9x)(0.9x)
Inogen0.3x0.3x36.7x33.8x
Lucid Diagnostics52.6x37.6x(4.4x)(4.7x)
Pro-Dex3.0x3.0x14.0x
Utah Medical3.1x8.3x
Surgical Science1.1x1.1x5.9x6.7x
Ilex Medical0.5x3.4x

This data is available for Pro users. Sign up to see all EBR Systems competitors and their valuation data.

Start Free Trial

EBR Systems Funding History

Before going public, EBR Systems raised $119M in total equity funding, across 4 rounds.


EBR Systems Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-19Undisclosed stageAscension Ventures; Brandon Capital; Emergent Medical Partners; M. H. Carnegie & Co.; Split Rock Partners$30MEBR Systems develops the WiSE CRT System, a wireless endocardial left ventricular (LV) pacing technology for cardiac resynchronization therapy (CRT) in heart failure patients, addressing limitations of traditional lead-based systems by delivering therapy directly to the left ventricle without transvenous leads. The company, founded with roots in biomedical innovation, targets the multi-billion-dollar cardiac rhythm management market, initially focusing on the US (50% of global CRT market) with an addressable market of US$2.5-2.6 billion and over 90,000 devices annually, expanding to Australia, UK, Germany, and France. Average selling price (ASP) upgraded to US$45,000 per device. On August 27, 2019, EBR Systems completed a debt financing round involving investors including Ascension Ventures, Brandon Capital, Emergent Medical Partners, M.H. Carnegie & Co., and Split Rock Partners, with Brandon Capital and M.H. Carnegie & Co. as leads. This followed prior equity rounds like Series F in 2017. The round supported ongoing development, including the SOLVE-CRT pivotal trial, which completed its randomized phase in 2020. Post-2019, EBR progressed commercialization efforts, listing on the ASX via a A$110 million IPO on November 24, 2021, at A$1.08 per CDI, backed by over A$30 million from existing investors like M.H. Carnegie, Brandon Capital, and super funds. Later financings included a $50 million placement in 2024 and $35 million in mid-2023. As of late 2024, cash balance was US$64.5 million, with revenue growing to US$4.25 million annually and major shareholders including Hostplus (11.5%), MH Carnegie Funds (11.0%), and Split Rock (7.2%). The company secured FDA approval pathways and focuses on US launch.
Nov-17Undisclosed stageAscension Ventures; Brandon Capital; M. H. Carnegie & Co.; Split Rock Partners; Thomas Fogarty$50M
Apr-15Undisclosed stageDelphi Ventures; Emergent Medical Partners; Split Rock Partners; St. Paul Venture Capital; SV Health Investors; Thomas Fogarty$20MEBR Systems, a developer of the WiSE wireless endocardial cardiac resynchronization therapy (CRT) pacing system, raised $20 million in venture funding around April 2015, led by Thomas Fogarty and joined by Delphi Ventures, Emergent Medical Partners, Split Rock Partners, St. Paul Venture Capital, and SV Health Investors. The funding supported development of its wireless pacing technology aimed at treating heart failure patients. Later rounds included a $50 million raise in an unspecified year led by M.H. Carnegie and Brandon Capital Partners. EBR Systems listed on the ASX in November 2021 via a A$110 million IPO, supported by prior investors including Brandon Capital and super funds contributing over A$30 million, to fund the SOLVE-CRT pivotal trial for FDA approval and U.S. commercialization. The initial addressable market was projected to grow to US$2.5 billion by 2024 from US$2.1 billion in 2019.
Jul-14Undisclosed stageDelphi Ventures; Split Rock Partners; St. Paul Venture Capital$19M

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About EBR Systems

When was EBR Systems founded?EBR Systems was founded in 2021.
Where is EBR Systems headquartered?EBR Systems is headquartered in United States.
How many employees does EBR Systems have?As of today, EBR Systems has over 89 employees.
Is EBR Systems publicly listed?Yes, EBR Systems is a public company listed on Australian Securities Exchange.
What is the stock symbol of EBR Systems?EBR Systems trades under EBR ticker.
When did EBR Systems go public?EBR Systems went public in 2021.
Who are competitors of EBR Systems?EBR Systems main competitors include Anika Therapeutics, Quantum-Si, Inogen, Lucid Diagnostics, Pro-Dex, Utah Medical, Surgical Science, Ilex Medical, Medinice, Zepp Health.
What is the current market cap of EBR Systems?EBR Systems' current market cap is $196M.
What is the current revenue of EBR Systems?EBR Systems' last 12 months revenue is $7M.
What is the current revenue growth of EBR Systems?EBR Systems revenue growth (NTM/LTM) is 278%.
What is the current EV/Revenue multiple of EBR Systems?Current revenue multiple of EBR Systems is 29.5x.
Is EBR Systems profitable?No, EBR Systems is not profitable.
What is the current EBITDA of EBR Systems?EBR Systems has negative EBITDA and is not profitable.
What is EBR Systems' EBITDA margin?EBR Systems' last 12 months EBITDA margin is (707%).
What is the current EV/EBITDA multiple of EBR Systems?Current EBITDA multiple of EBR Systems is (4.2x).
What is the current FCF of EBR Systems?EBR Systems' last 12 months FCF is ($56M).
What is EBR Systems' FCF margin?EBR Systems' last 12 months FCF margin is (819%).
What is the current EV/FCF multiple of EBR Systems?Current FCF multiple of EBR Systems is (3.6x).
How many companies EBR Systems has acquired to date?EBR Systems hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies EBR Systems has invested to date?EBR Systems hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to EBR Systems

Lists including EBR Systems

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial